You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 14, 2025

Drug Price Trends for CETIRIZINE-PSE ER


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for CETIRIZINE-PSE ER

Average Pharmacy Cost for CETIRIZINE-PSE ER

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
CETIRIZINE-PSE ER 5-120 MG TAB 45802-0147-53 0.55227 EACH 2025-01-22
CETIRIZINE-PSE ER 5-120 MG TAB 00536-1279-35 0.55227 EACH 2025-01-22
CETIRIZINE-PSE ER 5-120 MG TAB 45802-0147-62 0.55227 EACH 2025-01-22
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Cetirizine-Pseudoephedrine Extended Release (CETIRIZINE-PSE ER) Market Analysis and Price Projections

Overview of Cetirizine-Pseudoephedrine Extended Release

Cetirizine-pseudoephedrine extended release, commonly known by brand names such as Zyrtec-D and All Day Allergy-D, is a combination medication used to treat allergic rhinitis and other allergy symptoms. This drug combines the antihistamine cetirizine hydrochloride with the decongestant pseudoephedrine hydrochloride.

Market Drivers

Increasing Allergy Prevalence

The global market for cetirizine-pseudoephedrine ER is significantly driven by the rising prevalence of allergic diseases, including allergic rhinitis, eczema, and food allergies. According to the CDC, more than 1 in 4 American children and over 1 in 3 American adults reported having a food allergy, eczema, or seasonal allergy in 2021, which fuels the demand for effective treatments like cetirizine-pseudoephedrine ER[3].

Expansion of Over-the-Counter Availability

Regulatory approvals that expand over-the-counter access to cetirizine-pseudoephedrine ER in various regions have made the medication more accessible to consumers, boosting market penetration. This increased availability has been particularly beneficial in regions with well-established healthcare infrastructures, such as North America and Europe[1].

Advancements in Drug Formulations

Innovations in drug formulations, leading to the development of longer-lasting and faster-acting versions of cetirizine-pseudoephedrine ER, have enhanced its appeal and market share. These advancements cater to consumer demands for quick relief from allergy symptoms, further driving market growth[1].

Increased Healthcare Spending

Rising healthcare awareness and spending globally have led more individuals to seek effective solutions for allergy management. This trend favors the growth of the cetirizine-pseudoephedrine ER market, especially in regions with growing middle classes and improving healthcare infrastructures[1][3].

Regional Market Insights

North America

North America, particularly the U.S., leads in the adoption of cetirizine-pseudoephedrine ER due to high allergy prevalence and a well-established healthcare infrastructure. Significant healthcare spending and the extensive availability of over-the-counter allergy medications in this region contribute to its dominance in the market[1][3].

Europe

Europe shows strong market growth driven by increasing allergy rates and supportive healthcare policies. The presence of major pharmaceutical companies focused on R&D activities in regions like Germany and the UK also contributes to the robust market in Europe[1][3].

Asia Pacific

The Asia Pacific region is experiencing rapid market expansion due to increasing urbanization, air quality concerns, and rising allergy awareness. Countries like China and India are witnessing a surge in demand for allergy treatments, supported by improving healthcare access and public health awareness[1][3].

Middle East and Africa

The Middle East and Africa region is in its developmental stages, with market expansion potentially impacted by government healthcare efforts that enhance drug access and allergy awareness. However, this region presents significant growth potential as healthcare infrastructure improves[1][3].

Price Projections and Cost Analysis

Current Pricing

The cost for cetirizine-pseudoephedrine ER (5 mg-120 mg) oral tablet, extended release, is around $12 for a supply of 12 tablets, depending on the pharmacy. This pricing is for cash-paying customers and does not include insurance plans. Discounts and copay cards can reduce the cost significantly, with some programs offering savings of up to 80%[2].

Future Price Trends

Given the projected growth of the cetirizine hydrochloride market, which is expected to reach $8.0 billion by 2034 with a CAGR of 2.6%, prices are likely to remain competitive. The introduction of generic versions and increased competition in the market are expected to keep prices stable or even reduce them, making the medication more accessible to a broader range of consumers[3].

Market Size and Growth Projections

The global cetirizine hydrochloride market, which includes cetirizine-pseudoephedrine ER, was valued at $6.3 billion in 2024 and is projected to grow at a CAGR of 2.6% to reach $8.0 billion by 2034. This growth is driven by the increasing prevalence of allergic diseases, strategic expansions in emerging markets, and advancements in drug formulations[3].

Competitive Landscape

The market for cetirizine-pseudoephedrine ER is characterized by the presence of major pharmaceutical companies that engage in intensive marketing and educational campaigns to increase consumer awareness and trust in their products. Strategic partnerships between pharmaceutical companies and local distributors in various regions also enhance market reach and penetration[1][4].

Development of Combination Therapies

Combining cetirizine hydrochloride with other therapeutic agents to treat multiple symptoms offers a competitive edge and meets broader consumer needs. This trend is expected to continue, with pharmaceutical companies focusing on developing combination therapies that provide comprehensive relief from allergy symptoms[1].

Focus on Pediatric Allergy Treatments

There is a growing focus on pediatric allergy treatments, which presents an opportunity for cetirizine-pseudoephedrine ER formulations tailored for children. This segment is crucial as allergies among children are on the rise, and effective, child-friendly formulations can capture a significant market share[1].

Key Takeaways

  • Increasing Allergy Prevalence: Rising allergy rates globally drive the demand for cetirizine-pseudoephedrine ER.
  • Over-the-Counter Availability: Expanded OTC access increases market penetration.
  • Advancements in Formulations: Longer-lasting and faster-acting formulations enhance market appeal.
  • Regional Growth: North America, Europe, and Asia Pacific are key regions driving market growth.
  • Competitive Pricing: Generic versions and discounts keep prices competitive.
  • Market Size and Growth: Projected to reach $8.0 billion by 2034 with a CAGR of 2.6%.

FAQs

What is cetirizine-pseudoephedrine ER used for?

Cetirizine-pseudoephedrine ER is used to treat allergic rhinitis and other allergy symptoms by combining an antihistamine (cetirizine) with a decongestant (pseudoephedrine).

How much does cetirizine-pseudoephedrine ER cost?

The cost for cetirizine-pseudoephedrine ER (5 mg-120 mg) oral tablet, extended release, is around $12 for a supply of 12 tablets, but can be reduced with discounts and copay cards.

What regions are driving the growth of the cetirizine-pseudoephedrine ER market?

North America, Europe, and the Asia Pacific are the key regions driving the growth of the cetirizine-pseudoephedrine ER market.

What are the key drivers of the cetirizine-pseudoephedrine ER market?

Key drivers include increasing allergy prevalence, expanded over-the-counter availability, advancements in drug formulations, and increased healthcare spending.

What is the projected market size of the cetirizine hydrochloride market by 2034?

The global cetirizine hydrochloride market is projected to reach $8.0 billion by 2034 with a CAGR of 2.6%.

How does the competitive landscape of the cetirizine-pseudoephedrine ER market look?

The market is characterized by major pharmaceutical companies engaging in intensive marketing, educational campaigns, and strategic partnerships to enhance market reach and penetration.

Sources

  1. PharmiWeb: Cetirizine Hydrochloride Market Trends, Drivers, and Forecasts up to 2032[1].
  2. Drugs.com: Cetirizine/pseudoephedrine Prices, Coupons, Copay Cards & Patient Assistance[2].
  3. Prophecy Market Insights: Global Cetirizine Hydrochloride Market Size, Trends and Forecast to 2034[3].
  4. BioSpace: Cetirizine Hydrochloride Market Key Players, Sales, Demand, Dynamic Forces and Forecast 2029[4].
  5. FDA: ZYRTEC-D 12 HOUR Extended Release Tablets Label[5].

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.